scholarly journals Rare renal metastases from differentiated thyroid carcinoma: early clinical detection and treatment based on radioiodine

2014 ◽  
Vol 58 (3) ◽  
pp. 260-269 ◽  
Author(s):  
Zhong-Ling Qiu ◽  
Yan-Li Xue ◽  
Quan-Yong Luo
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Imaging Modality ◽  
Differentiated Thyroid Carcinoma ◽  
Renal Lesions ◽  
131I Treatment ◽  
Pet Ct ◽  
18F Fdg ◽  
Renal Metastases ◽  
Fdg Pet Ct

Objective : The aim of this study was to explore the clinical characteristics of renal metastatic cancer, the methods for its detection by radioiodine (131I), and the response to 131I treatment in fourteen patients with renal metastases from differentiated thyroid carcinoma (DTC).Subjects and methods : DTC patients (n = 2,955) that received treatment with 131I were retrospectively analyzed. Scans (131I-WBS, 31I-SPECT/CT and/or 18F-FDG-PET/CT) were performed after an oral therapeutic dose of 131I. Therapeutic efficacy was evaluated based on changes in Tg and anatomical imaging changes at renal lesions.Results : Among these 14 patients, 11 had avidity for 131I, but three patients did not accumulate 131I after 131I treatment. In the 11 131I-positive renal lesions, 10 cases were detected by 131I-SPECT/CT combined with another imaging modality and one case by 131I-WBS combined with ultrasonography (US). In the three 131I-negative renal lesions, two cases were detected by 18F-FDG-PET/CT and one case by computed tomography (CT). In 11 patients with 131I-avid renal metastases, Serum Tg levels in 81.82% (9/11) patients showed a gradual decline, and 18.18% (2/11) of the patients showed a significant elevation. There was no marked difference in serum Tg before the last 131I treatment (Z = 0.157; p = 0.875). Only one patient presented partial response, eight patients exhibited stable disease, and renal metastases progressed in two patients showing progressive disease. No patients reached complete response.Conclusion : 131I-SPECT/CT, combined with another imaging modality after 131I-WBS, can contribute to the early detection of renal metastases of DTC. 131I therapy is a feasible and effective treatment for most DTC renal metastases with avidity for 131I. Arq Bras Endocrinol Metab. 2014;58(3):260-9

scholarly journals Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients with Differentiated Thyroid Carcinoma

2012 ◽  
Vol 27 (9) ◽  
pp. 1019 ◽  
Author(s):  
Jandee Lee ◽  
Kuk Young Nah ◽  
Ra Mi Kim ◽  
Yeon-Ju Oh ◽  
Young-Sil An ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Differentiated Thyroid Carcinoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma

2013 ◽  
Vol 119 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Fabio Pomerri ◽  
Anna Rita Cervino ◽  
Faise Al Bunni ◽  
Laura Evangelista ◽  
Pier Carlo Muzzio
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Differentiated Thyroid Carcinoma ◽  
Therapeutic Impact ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma

2013 ◽  
Vol 34 (4) ◽  
pp. 340-346 ◽  
Author(s):  
Caroline Lansoy-Kuhn ◽  
Jean M. Picquenot ◽  
Agathe Edet-Sanson ◽  
Férial Mechken ◽  
Sophie Laberge-Le Couteulx ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Primary Tumour ◽  
Differentiated Thyroid Carcinoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Well Differentiated ◽  
Fdg Pet Ct

scholarly journals Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

2017 ◽  
Vol 61 (5) ◽  
pp. 416-425 ◽  
Author(s):  
Ji H. Yang ◽  
Rui M. B. Maciel ◽  
Claudia C. D. Nakabashi ◽  
Carolina C. P. S. Janovsky ◽  
Rosalia P. Padovani ◽  
...  
Keyword(s):  
High Risk ◽  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Clinical Utility ◽  
Differentiated Thyroid Carcinoma ◽  
Large Cohort ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Usefulness of PET/CT with 18F-FDG in Patients with Differentiated Thyroid Carcinoma after Radioiodine Therapy: An Italian Multicenter Study

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1264
Author(s):  
Luca Filippi ◽  
Viviana Frantellizzi ◽  
Fabio Monari ◽  
Elisa Lodi Rizzini ◽  
Elena Tabacchi ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Clinical Setting ◽  
Fdg Pet ◽  
Clinical Management ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Clinical Settings ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: our aim was to assess the diagnostic performance and clinical impact of 18F-FDG PET/CT in patients with differentiated thyroid carcinoma (DTC), previously treated with surgery and radioiodine therapy (RAI). Methods: patients subjected to 18F-FDG PET/CT for suspected DTC recurrence in three Italian nuclear medicine units were evaluated. Two different clinical settings were identified: clinical setting 1 included patients (n = 40) that were enrolled according to the American Thyroid Association guidelines (i.e., negative 1311-WBS and Tg level > 10 ng/mL); and clinical setting 2, that encompassed subjects (n = 26) with serum Tg ≤ 10 ng/mL but morphological findings suspected of relapse. PET/CT’s impact was scored as significant if it provided an indication for surgery, or led to a novel therapeutic decision. Results: In total, 51/66 patients (77.3%) were 18F-FDG positive, while 15 (22.7%) were negative. PET/CT showed an overall sensitivity and specificity of 84.4% and 75%, respectively. Sensitivity was higher in clinical setting 1 (89.1%) as compared to clinical setting 2 (76.1%), although this difference was not statistically significant (p = 0.83). PET/CT influenced clinical management in 28 cases (42.4%), without a significant difference between the 2 groups of patients (p = 0.6). Conclusions: our preliminary data, although limited by the retrospective nature of the study and possible selection bias, suggest that 18F-FDG PET/CT may be utilized for the detection of DTC recurrence in different clinical settings, with a meaningful impact on clinical management.

Sign in / Sign up

Export Citation Format

Share Document